Molecular Partners AG (XSWX:MOLN) Cash-to-Debt : 51.17 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Molecular Partners AG's cash to debt ratio for the quarter that ended in Dec. 2023 was 51.17.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Molecular Partners AG could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Molecular Partners AG's Cash-to-Debt or its related term are showing as below:

XSWX:MOLN' s Cash-to-Debt Range Over the Past 10 Years
Min: 21.99 Med: 5025.69 Max: No Debt
Current: 51.17

During the past 11 years, Molecular Partners AG's highest Cash to Debt Ratio was No Debt. The lowest was 21.99. And the median was 5025.69.

XSWX:MOLN's Cash-to-Debt is ranked better than
72.9% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs XSWX:MOLN: 51.17

Molecular Partners AG Cash-to-Debt Historical Data

The historical data trend for Molecular Partners AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Molecular Partners AG Cash-to-Debt Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

37.36

24.07

21.99

51.37

51.17

Molecular Partners AG Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															51.37	51.06	51.32	52.28	51.17

Competitive Comparison of Molecular Partners AG's Cash-to-Debt

For the Biotechnology subindustry, Molecular Partners AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Cash-to-Debt falls into.

Molecular Partners AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Molecular Partners AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	186.889	/	(1.208	+	2.444)
	=	51.17

Molecular Partners AG's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	186.889	/	(1.208	+	2.444)
	=	51.17

Molecular Partners AG (XSWX:MOLN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Molecular Partners AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.